Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the ...

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it ...

Pfizer recorded lower first-quarter revenue on a 75% drop in sales of its Covid-19 treatment, which more than offset growth ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Pfizer said Paxlovid sales fell $1.5 billion, or 75%, to roughly $500 million, partly due to a lower rate of COVID-19 infections in the U.S. and a drop in purchases by governments. To be sure ...

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects.

Pfizer recorded lower first-quarter revenue on a 75% drop in sales of its Covid-19 treatment, which more than offset growth in other drugs and product categories. The drugmaker posted a profit of ...